Brisbane biotech Vaxxas secures US patent for needle-free vaccine technology
Brisbane-based clinical-stage biotechnology company Vaxxas secured a new patent from the United States patent office covering its proprietary manufacturing technology for needle-free vaccine patches, the company announced on Wednesday. The patent covers Vaxxas’ printhead system that dispenses dried vaccine formulations onto the company’s high-density microarray patch (HD-MAP), which features thousands of microscopic projections on a…
